Is a Beat in the Cards for Incyte (INCY) in Q2 Earnings?

We expect Incyte Corporation (INCY) to surpass expectations when it reports second-quarter 2024 results on Jul 30, before the opening bell. Incyte primarily derives product revenues from the sales of its lead drug, Jakafi (ruxolitinib), in the United States and other marketed drugs. Incyte earns product royalty revenues from Novartis AG (NVS) for the commercialization of Jakafi in ex-U.S. markets. Novartis licensed ruxolitinib for its development and commercialization outside the United States. Incyte also ...